About Unijules Life Sciences Limited
Data last updated:
Unijules Life Sciences Limited is a public limited company based in Nagpur, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 16 January 2006 and has been in existence for over 20 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U52311MH2006PLC158928. Its GSTIN is 27AAACU8032D1ZK (Maharashtra).
The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹13.86 Cr. It is led by directors including Pawan Kumar Chokhani and Pranav Pawan Chokhani.
Its last annual general meeting (AGM) was held on 30 September 2018, and its latest financial statements are for the year ended 31 March 2018. The registered office is at B – 35 MIDC Industrial Area Kalmeshwar, Nagpur, Maharashtra, India – 441501.
As per the financials filed for FY 2018, the company reported a revenue of ₹61.64 Cr, a decline of 4% compared to the previous year. For the same year it recorded a net loss of ₹10.68 Cr (net margin -17.3%) and EBITDA of ₹3.69 Cr (EBITDA margin 6%). Revenue has declined at a compounded annual rate (CAGR) of 4% over three years.
The company has about 57 employees on its provident fund (EPFO) records.
The company is associated with 3 brands: Neo Karnim, Unijules Life Sciences and Karnim. As per MCA filings, the company has open charges of ₹817.76 Cr and satisfied charges of ₹49.75 Cr on record. Court records list 74 cases involving the company, including 24 filed by the company and 50 filed against it; 16 cases are pending. The company has 8 deals on record (4 funding rounds, 4 secondary share transfers), with disclosed funding of ₹31.86 Cr; the latest was in March 2013. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Cian Healthcare Limited with revenue of ₹62.14 Cr.
The current compliance status is marked as active non-compliant by the Registrar of Companies. For more details, the company can be reached via its website unijules.com.
Company details
CIN history
Unijules Life Sciences has one previous CIN (Corporate Identification Number): U52311MH2005PLC158928. The current CIN is U52311MH2006PLC158928, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U52311MH2006PLC158928 | Current |
| U52311MH2005PLC158928 | Previous |
Contact details
Unijules Life Sciences Limited's registered office is in Nagpur, Maharashtra. Its website is unijules.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressB – 35 MIDC Industrial Area Kalmeshwar, Nagpur, Maharashtra, India – 441501
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Unijules Life Sciences Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Unijules Life Sciences operates multiple associated brands including Neo Karnim, Unijules Life Sciences, and Karnim. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Herbal capsules for controlling blood sugar and supporting diabetes care. | neokarnim.com | |
| Manufactures allopathic and herbal products, provides research and technical services. | unijules.com | |
| Produces and sells herbal products for diabetes management and Ayurvedic formulations. | karnim.com |
Business activity
The main business activity of Unijules Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Unijules Life Sciences Limited, buy the company report.
Financials of Unijules Life Sciences Limited
FY 2018 filings availableUnijules Life Sciences Limited reported revenue of ₹61.64 Cr (down 4% YoY) for FY 2018.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 4% over three years, including a 4% fall in the latest year. EBITDA fell 8% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ₹61.64 Cr | |||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ₹3.69 Cr | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | -₹10.68 Cr | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 6% | |||
| Net Profit Margin | -17.3% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Unijules Life Sciences Limited, buy the company report.
Board of directors of Unijules Life Sciences Limited
Unijules Life Sciences has 3 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pawan Kumar Chokhani | Director | 01 Jan 2026 | 0 Years 10 Months | Current |
| Pranav Pawan Chokhani | Director | 01 Jan 2026 | 0 Years 10 Months | Current |
| Ankit Pawan Chokhani | Director | 01 Jan 2026 | 0 Years 10 Months | Current |
Peer comparison
Unijules Life Sciences Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Cian Healthcare Limited | ₹62.14 Cr (FY 2024) | -10.0% | Pune, Maharashtra, India | |||
| Enanti Labs Private Limited | ₹62.07 Cr (FY 2025) | -14.0% | Hyderabad, Telangana, India | |||
| MDC Pharmaceuticals Limited | ₹61.89 Cr (FY 2024) | 14.0% | Chandigarh, India | |||
| DNV Overseas Impex Private Limited | ₹61.67 Cr (FY 2018) | 74.0% | New Delhi, Delhi, India | |||
| Unijules Life Sciences Limitedthis company | ₹61.64 Cr (FY 2018) | -₹10.68 Cr | -17.3% | -4.0% | 57 | Nagpur, Maharashtra, India |
| Revat Laboratories Private Limited | ₹61.45 Cr (FY 2025) | 10.0% | Hyderabad, Telangana, India | |||
| Gelnova Laboratories (India) Private Limited | ₹61.38 Cr (FY 2025) | -4.0% | Navi Mumbai, Maharashtra, India | |||
| Mistair Health and Hygiene Private Limited | ₹61.27 Cr (FY 2025) | -21.0% | Mumbai, Maharashtra, India | |||
| Gentech Healthcare Private Limited | ₹61.04 Cr (FY 2025) | 15.0% | New Delhi, Delhi, India |
To see the full peer comparison of Unijules Life Sciences Limited, buy the company report.
Auditor
Unijules Life Sciences Limited is audited by Milind Mehta & Co for the financial year 2018.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Milind Mehta & Co | FY 2018 | 129664W |
Shareholding
The shareholding of Unijules Life Sciences Limited is on record for 4 financial years, the latest being FY 2018, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Unijules Life Sciences Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 15 Apr 2014 | 10497128 | Others | ₹4 Cr | Open | |
| 26 Mar 2013 | 10427281 | Punjab National Bank | ₹48 Cr | Open | |
| 17 Sep 2012 | 10376918 | Yes Bank Limited | ₹10 Cr | Open | |
| 29 Aug 2012 | 10377122 | Bank of Maharashtra | ₹43 Cr | Open | |
| 28 Mar 2012 | 10356491 | Others | ₹4.25 Cr | Open |
To see the full charge records of Unijules Life Sciences Limited, buy the company report.
Total charge records: 29 View all charges
Deals & funding
Unijules Life Sciences Limited has 8 deals on record (4 funding rounds, 4 secondary share transfers), with disclosed funding of ₹31.86 Cr; the latest was in March 2013.
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2013 | Secondary share transfer | Undisclosed | Buyer: Aritra Investment and Trading Private Limited Seller: Benzo Petro International Limited , Virtuous Capital Limited , Astra Exim Private Limited |
| Sep 2012 | Secondary share transfer | Undisclosed | Buyer: Pranav Financial Services Private Limited Seller: Aritra Investment and Trading Private Limited |
| Aug 2012 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Aritra Investment and Trading Private Limited |
| Mar 2010 | Secondary share transfer | Undisclosed | Buyer: Virtuous Capital Limited Seller: Finaventure Capital Limited , an individual |
| Mar 2010 | Funding round | ₹7.26 Cr | Investors: Benzo Petro International Limited |
To see the full deal history of Unijules Life Sciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Unijules Life Sciences Limited has 74 court cases on record: 24 filed by Unijules Life Sciences, 50 filed against it. 16 cases are pending and 58 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 41 | 32 | 12 |
| High courts | 24 | 9 | 4 |
| NCLAT | 4 | 4 | 0 |
| NCLT | 3 | 3 | 0 |
| Supreme Court | 2 | 2 | 0 |
Cases on record (5 of 74)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Nagpur, Maharashtra | Court case (Reg Dkst) | Filed against the company by M/S Pearl Polymers Ltd | Pending |
| NCLAT, NCLAT New Delhi | Insolvency matter | Filed against the company by Adroit Pharmaceuticals Pvt Ltd | Disposed |
| NCLAT, NCLAT New Delhi | Interim or miscellaneous application | Filed against the company by Adroit Pharmaceuticals Pvt Ltd | Disposed |
| NCLAT, Chairperson Court | Tribunal matter | Filed against the company by Asset Reconstruction Company India Ltd | Disposed |
| High Court of Delhi | Commercial suit | Filed against the company by Emcure Pharmaceuticals Limited | Disposed |
To see the full case history of Unijules Life Sciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Unijules Life Sciences Limited was last rated by Crisil on 24 Nov 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 24 Nov 2020 |
To see the full credit ratings and regulatory alerts of Unijules Life Sciences Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Unijules Life Sciences Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Unijules Life Sciences Limited has a workforce of 57 employees on its EPFO records as of Jan 19, 2026, across 1 active EPFO establishment.
GST
Unijules Life Sciences has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACU8032D1ZK | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Unijules Life Sciences Limited, buy the company report.
Recent activity
Unijules Life Sciences Limited has 27 board changes on record since 2006: 8 appointments and 19 cessations. The latest: Ankit Pawan Chokhani was appointed as Director on 01 Jan 2026.
62 earlier events are in the company report.
Frequently asked questions
Unijules Life Sciences is an active public limited company based in Nagpur, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 16 January 2006 (20+ years old) and is registered under CIN U52311MH2006PLC158928.
Unijules Life Sciences has 3 current directors:
- Pawan Kumar Chokhani - Director
- Pranav Pawan Chokhani - Director
- Ankit Pawan Chokhani - Director
The latest financial statements of Unijules Life Sciences on record with the MCA are for the year ended 31 March 2018. Its last annual general meeting was held on 30 September 2018. Year-wise statements from 2015 are in the company report.
The GSTIN of Unijules Life Sciences is 27AAACU8032D1ZK, registered in Maharashtra.
The CIN (Corporate Identification Number) of Unijules Life Sciences is U52311MH2006PLC158928. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Unijules Life Sciences has 74 court cases on record: 24 filed by the company and 50 filed against it. 16 are pending. Most are in the district courts.
Unijules Life Sciences was incorporated on 16 January 2006, making it 20+ years old. It is registered with the Registrar of Companies, Mumbai.
Unijules Life Sciences has 8 deals on record (4 funding rounds, 4 secondary share transfers), with disclosed funding of ₹31.86 Cr; the latest was in March 2013.
The peers of Unijules Life Sciences by revenue are Cian Healthcare Limited, Enanti Labs Private Limited, MDC Pharmaceuticals Limited, DNV Overseas Impex Private Limited, Revat Laboratories Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Ankit Pawan Chokhani was appointed as Director on 01 Jan 2026. Pawan Kumar Chokhani was appointed as Director on 01 Jan 2026. Pranav Pawan Chokhani was appointed as Director on 01 Jan 2026. Unijules Life Sciences has 27 board changes on record in total.
Unijules Life Sciences can be reached through the website unijules.com. Its registered office is in Nagpur, Maharashtra, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
